神经内分泌肿瘤¹⁷⁷Lu-DOTA-TATE治疗中SPECT/CT吸收剂量与SUV及疗效的关系
本研究纳入22例接受[¹⁷⁷Lu]Lu-DOTA-TATE治疗的神经内分泌肿瘤患者,基于SPECT/CT测算靶病灶吸收剂量与SUV,分析其与疗效的关系。第1至4周期靶病灶吸收剂量分别为21.0、16.0、11.4、8.8 Gy;吸收剂量与SUV均与肿瘤部分缓解率呈S形曲线关系,且第1至4周期两者线性相关R²为0.7、0.8、0.8、0.9。
要点
- 22例NENs患者PRRT第1至4周期靶病灶吸收剂量分别为21.0、16.0、11.4、8.8 Gy。
- 靶病灶吸收剂量与SUV均与肿瘤部分缓解率呈S形曲线关系。
- 第1至4周期吸收剂量与SUV线性相关,R²分别为0.7、0.8、0.8、0.9。
核心结论
- 基于SPECT/CT的PRRT剂量学分析中,靶病灶吸收剂量与SUV可为核素治疗提供重要剂量指导,有助于提高疗效。
研究设计与样本
- 本研究纳入22例接受[¹⁷⁷Lu]Lu-DOTA-TATE治疗并在给药后连续行SPECT/CT显像的神经内分泌肿瘤患者。
- 使用Hermes Internal Radiation Dosimetry(HIRD)软件勾画靶器官与靶病灶VOI并计算吸收剂量,在重建SPECT/CT融合图像上测量靶病灶SUV。
- 分别分析吸收剂量、SUV与患者疗效之间的相关性。
主要发现
- 患者接受第1至4周期[¹⁷⁷Lu]Lu-DOTA-TATE治疗后,肿瘤靶病灶吸收剂量分别为21.0、16.0、11.4、8.8 Gy。
- 吸收剂量与SUV均与肿瘤部分缓解(PR)率呈「S」形曲线关系。
- 第1至4次PRRT治疗中,吸收剂量与SUV呈线性相关,R²分别为0.7、0.8、0.8、0.9。
临床怎么用
- 在PRRT过程中可基于SPECT/CT连续开展剂量学计算,结合靶病灶吸收剂量与SUV为核素治疗提供剂量指导。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The aim of this study was to evaluate the efficacy of neuroendocrine neoplasms (NENs) patients treated with peptide receptor radionuclide therapy (PRRT), and to investigate the relationships among the absorbed dose of the tumor target lesions, standardized uptake value (SUV), and the therapeutic efficacy of the patients. A total of 22 NENs patients who received [177Lu]Lu-DOTA-TATE treatment and underwent consecutive single-photon emission computed tomography/computed tomography (SPECT/CT) imaging after drug administration were included in this study. After the SPECT/CT imaging, the volume of interest (VOI) of the target organs and the target lesions were delineated using the Hermes Internal Radiation Dosimetry (HIRD) software, and their absorbed doses were calculated. The SUV of the target lesions was measured on the reconstructed SPECT/CT fusion images. We conducted studies on the correlations between the absorbed dose, SUV, and the therapeutic efficacy of the patients respectively. RESULTS: After the patients received [177Lu]Lu-DOTA-TATE treatment in cycles 1 to 4, the absorbed doses of the tumor target lesions were 21.0, 16.0, 11.4, and 8.8 Gy respectively. The results of the correlations between the absorbed dose, SUV, and the therapeutic efficacy of the patients showed that both the absorbed dose and SUV had an "S"-shaped curve relationship with the tumor partial response (PR) rate. In addition, for the 1st to 4th PRRT treatments, the absorbed dose and SUV were linearly correlated with R2 of 0.7, 0.8, 0.8, and 0.9, respectively. CONCLUSIONS: Through the calculation and analysis of the radionuclide therapy dosimetry based on the SPECT/CT images throughout the PRRT treatment of the patients, the absorbed dose and SUV of the patients can provide important dose guidance for radionuclide therapy, which is helpful to improve the treatment efficacy of the patients. TRIAL REGISTRATION: A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs, NCT05459844. Registered 5 July 2022, https://clinicaltrials.gov/study/NCT05459844?cond=NCT05459844&rank=1 .
引用
- Liu F, Yang H, Zhang J, et al. Relationship between absorbed dose and SUV derived from SPECT/CT imaging and dose-response in patients with neuroendocrine tumors treated with [¹⁷⁷Lu]Lu-DOTA-TATE. EJNMMI Res. 2026. PMID: 41739362. doi:10.1186/s13550-026-01402-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。